# CJC-1295 half life: Pharmacokinetics in the Research Record

> CJC-1295 half life in the research literature: the DAC form's estimated 5.8-8.1 day half-life and IGF-1 elevation to ~28 days (Teichman 2006), versus the short-acting no-DAC form. The decay, by state.

The DAC variant's multi-day half-life is the central fact of this compound. Here is the absorption, the plateau, and the albumin-paced decay — stepped through day by day, all from the published human data.

## The CJC-1295 half life, measured

The defining property of this compound is its **CJC-1295 half life**. For the DAC variant, the estimated plasma half-life is 5.8 to 8.1 days in healthy adults [1]. That is not a typo or a forum estimate — it comes from the pharmacokinetic analysis of single and multiple subcutaneous doses, the same study in which IGF-1 stayed above baseline for up to 28 days after repeat dosing [1].

The mechanism behind that number is the whole story. The DAC variant carries a maleimidopropionyl-lysine handle that forms a covalent bond with a free thiol on circulating serum albumin, producing a peptide-albumin conjugate whose plasma residence approaches that of albumin itself [2]. Because albumin turns over on a scale of days, the conjugated peptide does too. The four protease-resistant substitutions — chiefly D-Ala at position 2 — keep dipeptidylpeptidase-IV from cleaving the molecule before albumin can capture it [7][8]. Strip the albumin handle and you strip the multi-day duration: that is exactly what distinguishes the no-DAC form.

## How long does CJC-1295 stay in the body?

### How long does CJC-1295 stay in the body?

It depends on the variant. The DAC form has an estimated half-life of 5.8-8.1 days, with IGF-1 elevation persisting up to approximately 28 days after multiple doses [1], because it is covalently bound to serum albumin. The no-DAC "Modified GRF 1-29" is short-acting (minutes-to-hours), reflecting native GHRH(1-29) clearance with protease-resistant substitutions [8][9].

Walk the DAC variant's timeline as a sequence of states. **Day 0:** a single subcutaneous dose is absorbed and GH rises 2- to 10-fold; the pituitary keeps pulsing rather than flat-lining [1][3]. **Day 7:** mean GH is still elevated — about 46% above baseline at one week in the 60-90 microgram/kg study — and IGF-1 runs roughly 1.5- to 3-fold over baseline [3][1]. **Day 28:** after multiple doses, IGF-1 is still measurable above baseline, the long tail produced by the albumin conjugate [1]. The no-DAC form has no such tail; it follows native GHRH(1-29) clearance, which is a matter of minutes to hours [8].

## Why native GHRH needed re-engineering

The long-acting design exists because the unmodified hormone is fragile. Native human GHRH(1-29)-NH2 is degraded rapidly in plasma, primarily by dipeptidylpeptidase-IV and trypsin-like enzymes, which is why unmodified GRF(1-29) has a very short half-life [8]. Early pharmacokinetic work in healthy men quantified that short circulating half-life directly and motivated the long-acting analog program [10].

Two engineering strategies followed. The first was substitution: incorporating D-Ala at position 2 of GHRH(1-29)-NH2 markedly increases plasma half-life and potency by resisting DPP-IV cleavage — the change that underlies "Modified GRF (1-29)" and the no-DAC stability profile [7]. The second was half-life extension by attachment. PEGylation of GHRH analogues was explored as one route [12]; CJC-1295's albumin bioconjugation (DAC) was the route that worked, carrying the peptide to a multi-day half-life [2]. The substitutions buy minutes-to-hours of stability; the albumin conjugation buys days.

## What to expect when taking CJC-1295?

### What to expect when taking CJC-1295?

The measured physiology in studies is elevated GH and IGF-1 with preserved pulsatility [3], with the DAC variant's effect spread over days because of its long half-life [1]. Beyond those biomarkers, controlled long-term outcome data in healthy adults do not exist, so claims about body composition or "anti-aging" outrun the evidence.

That is the honest boundary of the pharmacokinetics. The studies establish what the GH and IGF-1 curves do; they do not establish what those curves mean for muscle, fat, recovery, or longevity in healthy people, because no controlled outcome trial in that population was run [1]. CJC-1295 has no approved human use, and the figures on this page describe research methodology, not a course of administration.

---

The CJC-1295 record read as a state machine — each figure logged to its study and tagged confirmed, the absent long-term human safety data left in plain view as the loudest state on the panel; no clinic behind the interface and nothing here dispensed or sold.